{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:24Z","timestamp":1792784844115,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50-CA100707-18"],"award-info":[{"award-number":["P50-CA100707-18"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50-CA100707-18"],"award-info":[{"award-number":["P50-CA100707-18"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01:CA 155258"],"award-info":[{"award-number":["P01:CA 155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"a Paula and Rodger Riney Foundation Grant and Adelson Program in Multiple Myeloma Research grant","id":[{"id":"https:\/\/ror.org\/050a7g229","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple myeloma (MM) is a plasma cell malignancy characterized by genomic instability and a high dependency on proteasome activity. Accordingly, DNA-damaging agents and proteasome inhibitors (PIs) are frontline therapies; however, therapeutic resistance inevitably develops. RAD23A, a dual-function protein involved in nucleotide excision repair and proteasome-mediated protein degradation, is highly expressed in MM and is associated with poor patient survival. Here, we demonstrate that depletion of RAD23A exerts potent anti-MM activity both in vitr\n                    <jats:italic>o<\/jats:italic>\n                    and in\n                    <jats:italic>vivo<\/jats:italic>\n                    . Inducible CRISPR\/Cas9 knockout (iKO) or shRNA-mediated knockdown of RAD23A in MM cell lines, including PI-resistant models, markedly suppressed cell proliferation. RAD23A loss impaired DNA repair capacity, triggered activation of the stress-associated eIF2\u03b1\u2013ATF4 axis and promoted caspase-dependent apoptosis. Quantitative proteomic profiling of RAD23A-iKO cells confirmed upregulation of apoptotic and stress-response pathways, accompanied by downregulation of DNA repair and deubiquitination pathways. In an MM xenograft model, RAD23A depletion significantly reduced tumor growth and prolonged survival. Collectively, these findings identify RAD23A as a critical survival factor in MM and highlight its potential as a novel therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41408-026-01574-z","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:17:26Z","timestamp":1784135846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Xueping","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3401-5446","authenticated-orcid":false,"given":"Minxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-2905","authenticated-orcid":false,"given":"Arghya","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-0078","authenticated-orcid":false,"given":"Md Abu","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-1564","authenticated-orcid":false,"given":"Filip","family":"Garbicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-1852","authenticated-orcid":false,"given":"Ruben D.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil A.","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-9742","authenticated-orcid":false,"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-2672","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1574_CR1","doi-asserted-by":"crossref","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45.","DOI":"10.1038\/s41572-024-00529-7"},{"key":"1574_CR2","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.3390\/cancers15164155","volume":"15","author":"C Petrilla","year":"2023","unstructured":"Petrilla C, Galloway J, Kudalkar R, Ismael A, Cottini F. Understanding DNA damage response and DNA repair in multiple myeloma. Cancers (Basel). 2023;15:4155.","journal-title":"Cancers (Basel)"},{"key":"1574_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783\u201392.","journal-title":"Cancer Res"},{"key":"1574_CR4","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","volume":"22","author":"KC Anderson","year":"2016","unstructured":"Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22:5419\u201327.","journal-title":"Clin Cancer Res"},{"key":"1574_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Medical progress multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"1574_CR6","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609\u201317.","journal-title":"N Engl J Med"},{"key":"1574_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12:42\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"1574_CR8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/j.1460-2075.1994.tb06452.x","volume":"13","author":"C Masutani","year":"1994","unstructured":"Masutani C, Sugasawa K, Yanagisawa J, Sonoyama T, Ui M, Enomoto T, et al. Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J. 1994;13:1831\u201343.","journal-title":"EMBO J"},{"key":"1574_CR9","doi-asserted-by":"publisher","first-page":"12694","DOI":"10.1073\/pnas.1634989100","volume":"100","author":"KJ Walters","year":"2003","unstructured":"Walters KJ, Lech PJ, Goh AM, Wang Q, Howley PM. DNA-repair protein hHR23a alters its protein structure upon binding proteasomal subunit S5a. Proc Natl Acad Sci. 2003;100:12694\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"1574_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/35661","volume":"391","author":"C Schauber","year":"1998","unstructured":"Schauber C, Chen L, Tongaonkar P, Vega I, Lambertson D, Potts W, et al. Rad23 links DNA repair to the ubiquitinproteasome pathway. Nature. 1998;391:715\u20138.","journal-title":"Nature"},{"key":"1574_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.201107050","volume":"196","author":"S Bergink","year":"2012","unstructured":"Bergink S, Toussaint W, Luijsterburg MS, Dinant C, Alekseev S, Hoeijmakers JHJ, et al. Recognition of DNA damage by XPC coincides with disruption of the XPC-RAD23 complex. J Cell Biol. 2012;196:681\u20138.","journal-title":"J Cell Biol"},{"key":"1574_CR12","doi-asserted-by":"crossref","unstructured":"Guo X, Prajapati R, Chun J, Byun I, Gebis KK, Wang Y-Z et al. Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy. Nat Commun. 2026;17:1820.","DOI":"10.1038\/s41467-025-65104-4"},{"key":"1574_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/16078454.2021.1997196","volume":"26","author":"S Park","year":"2021","unstructured":"Park S, Kim YJ, Huh HJ, Chung HS, Lee M, Park YM, et al. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia. Hematol (U Kingd). 2021;26:904\u201313.","journal-title":"Hematol (U Kingd)"},{"key":"1574_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2025.103857","volume":"152","author":"H Liu","year":"2025","unstructured":"Liu H, Li Z, Wang Y, Li C, Yan K, Ma Y. DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing. DNA Repair (Amst). 2025;152:103857.","journal-title":"DNA Repair (Amst)"},{"key":"1574_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41375-019-0498-5","volume":"34","author":"S Adamia","year":"2020","unstructured":"Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, et al. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020;34:167\u201379.","journal-title":"Leukemia"},{"key":"1574_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41592-020-0781-4","volume":"17","author":"J Li","year":"2020","unstructured":"Li J, Van Vranken JG, Pontano Vaites L, Schweppe DK, Huttlin EL, Etienne C, et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat Methods. 2020;17:399\u2013404.","journal-title":"Nat Methods"},{"key":"1574_CR17","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"1574_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"1574_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-4939-6783-4_11","volume":"1558","author":"G Wu","year":"2017","unstructured":"Wu G, Haw R. Functional Interaction Network Construction and Analysis for Disease Discovery. Methods Mol Biol. 2017;1558:235\u201353.","journal-title":"Methods Mol Biol"},{"key":"1574_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1574_CR21","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1093\/bioinformatics\/btx441","volume":"33","author":"K Sidiropoulos","year":"2017","unstructured":"Sidiropoulos K, Viteri G, Sevilla C, Jupe S, Webber M, Orlic-Milacic M, et al. Reactome enhanced pathway visualization. Bioinformatics. 2017;33:3461\u20137.","journal-title":"Bioinformatics"},{"key":"1574_CR22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"M Waskom","year":"2021","unstructured":"Waskom M. seaborn: statistical data visualization. J Open Source Softw. 2021;6:3021.","journal-title":"J Open Source Softw"},{"key":"1574_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter JD. Matplotlib: A 2D graphics environment. Comput Sci Eng. 2007;9:90\u201395.","journal-title":"Comput Sci Eng"},{"key":"1574_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood.2023022777","volume":"143","author":"A Gulla","year":"2024","unstructured":"Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, et al. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024;143:2612\u201326.","journal-title":"Blood"},{"key":"1574_CR25","doi-asserted-by":"publisher","first-page":"e1453","DOI":"10.21769\/BioProtoc.1453","volume":"5","author":"J-M Park","year":"2015","unstructured":"Park J-M, Kang T-H. DNA slot blot repair assay. Bio Protoc. 2015;5:e1453\u2013e1453.","journal-title":"Bio Protoc"},{"key":"1574_CR26","first-page":"2599","volume":"141","author":"T Du","year":"2023","unstructured":"Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, et al. Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023;141:2599\u2013614.","journal-title":"Blood"},{"key":"1574_CR27","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41375-018-0116-y","volume":"32","author":"MK Samur","year":"2018","unstructured":"Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, et al. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018;32:2626\u201335.","journal-title":"Leukemia"},{"key":"1574_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2023.194932","volume":"1866","author":"SH Park","year":"2023","unstructured":"Park SH, Lee S-E, Jeon JH, Lee JH, Itakura E, Chang S, et al. Formation of aggresomes with hydrogel-like characteristics by proteasome inhibition. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2023;1866:194932.","journal-title":"Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms"},{"key":"1574_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tcb.2021.02.005","volume":"31","author":"A He","year":"2021","unstructured":"He A, Dean JM, Lodhi IJ. Peroxisomes as cellular adaptors to metabolic and environmental stress. Trends Cell Biol. 2021;31:656\u201370.","journal-title":"Trends Cell Biol"},{"key":"1574_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-020-00679-2","volume":"27","author":"T Takahara","year":"2020","unstructured":"Takahara T, Amemiya Y, Sugiyama R, Maki M, Shibata H. Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes. J Biomed Sci. 2020;27:87.","journal-title":"J Biomed Sci"},{"key":"1574_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02295-w","volume":"24","author":"B Lu","year":"2025","unstructured":"Lu B, Chen S, Guan X, Chen X, Du Y, Yuan J, et al. Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer. Mol Cancer. 2025;24:83.","journal-title":"Mol Cancer"},{"key":"1574_CR32","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.bbrc.2016.09.025","volume":"478","author":"X Tan","year":"2016","unstructured":"Tan X, Wang H-C, Liang R-Y, Chuang S-M. Human Rad23A plays a regulatory role in autophagy. Biochem Biophys Res Commun. 2016;478:1772\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1574_CR33","doi-asserted-by":"crossref","unstructured":"Tonon G Myeloma and DNA damage. Blood. 2024;143: 488-95.","DOI":"10.1182\/blood.2023021384"},{"key":"1574_CR34","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.18632\/oncotarget.1740","volume":"5","author":"A Kassambara","year":"2014","unstructured":"Kassambara A, Gourzones-Dmitriev C, Sahota S, R\u00e8me T, Moreaux J, Goldschmidt H, et al. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget. 2014;5:2487\u201398.","journal-title":"Oncotarget"},{"key":"1574_CR35","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1073\/pnas.1915534117","volume":"117","author":"GA Collins","year":"2020","unstructured":"Collins GA, Goldberg AL. Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation. Proc Natl Acad Sci. 2020;117:4664\u201374.","journal-title":"Proc Natl Acad Sci"},{"key":"1574_CR36","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/onc.2017.172","volume":"36","author":"Y Song","year":"2017","unstructured":"Song Y, Li S, Ray A, Das DS, Qi J, Samur MK, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017;36:5631\u20138.","journal-title":"Oncogene"},{"key":"1574_CR37","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2016.97","volume":"30","author":"Y Song","year":"2016","unstructured":"Song Y, Ray A, Li S, Das DS, Tai YT, Carrasco RD, et al. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia. 2016;30:1877\u201386.","journal-title":"Leukemia"},{"key":"1574_CR38","doi-asserted-by":"crossref","unstructured":"Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, et al. Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma. Blood. 2026;147:2344-57","DOI":"10.1182\/blood.2025029358"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01574-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01574-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01574-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:52:58Z","timestamp":1791514378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01574-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01574-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KCA is a consultant to Pfizer, AstraZeneca, Janssen, and Genentech; is a Board member of C4 Therapeutics, Dynamic Cell Therapies, Window Therapeutics, and Starton; and is an equity owner in C4 Therapeutics, Dynamic Cell Therapies, Window Therapeutics, Starton, and Predicta. NCM is a consultant for BMS, Johnson & Johnson Innovative Medicine, OncoPep, Amgen, Karyopharm, Legend, AbbVie, Takeda, and GlaxoSmithKline (GSK); and serves on the board of directors of, and has stock options in, OncoPep. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"175"}}